Hartley said gross profit was negatively impacted by $1.9 million in one-time costs in the fourth quarter associated with the BLA approval, two-thirds of which were non-cash stock-based compensation tied to milestone vesting. Excluding one-time items, she attributed margin pressure mainly to higher product costs related to additional testing steps as Avance transitioned to a biologic, partially offset by fewer inventory write-offs and lower shipping costs following the case stock program’s discontinuation.G ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAnthony Petrone - Managing DirectorCaitlin Roberts - DirectorJayson Bedford - Managing DirectorJens Schoener - CMOLindsey Hartley - CFOMichael Dale - CEORick Ditto - Medical Device & Life Science ExecutiveSimran Kaur - VPConference Call ParticipantsChris Pasquale - Senior AnalystFrank Takkinen - Senior Research AnalystMichael Sarcone - AnalystMike Kratky - AnalystOperatorGood morning, everyone. Joining me on today ...